miR-21 inhibition reverses doxorubicin-resistance and inhibits PC3 human prostate cancer cells proliferation

Andrologia. 2021 Jun;53(5):e14016. doi: 10.1111/and.14016. Epub 2021 Feb 17.

Abstract

Many approaches have been examined to reversing multidrug resistance (MDR), but sub-optimal target-based strategies have limited their efficacy. Herein, we investigate microRNA (miR-21) suppression on the doxorubicin (DOX)-sensitisation of the DOX-resistant (PC3/DOX) cell line in prostate cancer (PCa). Expression levels of miR-21, P-glycoprotein (P-gp), MDR-1 and PTEN evaluated in PC3/DOX cancer cells by qRT-PCR and western blot analyses. The cytotoxic effects of transfected of miR-21 were assessed by MTT assay for 72 hr. Rhodamine123 (Rh123) assay was employed to define the activity of P-gp. Apoptosis was detected by Flow cytometry. As expected, miR-21 was expressed highly in PC3/DOX cells (p < 0.05). It was shown that miRNA-21 suppression considerably hindered PC3/DOX cell viability. miR-21 suppression dramatically downregulated P-gp expression and activity in DOX-resistance cells and abolished MDR by an increment of intracellular accumulation of DOX in PC3/DOX cells (p < 0.05). PTEN is a key modulator of the PI3K/Akt/P-gp cascade, which miR-21 suppression led to the upregulation of PTEN and sequentially lower-expression of P-gp that reversed MDR. Also, miR-21 repression enhanced the apoptosis rate of PC3/DOX cells. The findings of this paper contribute to the current understanding of the functions of miR-21 in MDR-reversing in PCa.

Keywords: Akt; PI3K; PTEN; doxorubicin; miR-21; prostate cancer.

MeSH terms

  • Apoptosis
  • Cell Line, Tumor
  • Cell Proliferation
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Male
  • MicroRNAs* / genetics
  • Phosphatidylinositol 3-Kinases / genetics
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / genetics

Substances

  • MIRN21 microRNA, human
  • MicroRNAs
  • Doxorubicin

Grants and funding